ClinicalTrials.gg
CompletedNCT05852951Updated May 10, 2023

Cycle and Ovulation Study Expansion

An observational study in Menstruation, sponsored by Apple Inc.. Completed at 1 site in United States. Open to female participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by Apple Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
698
Ages
14 Years and older
Sex
Female
01

Study summary

The objective of this study was to collect menstrual cycle, health sensor data and general health information to understand correlations between menstrual cycle and health sensor data, and how those correlations may be affected by general health. Participants entered menstrual cycle information (such as start dates, end dates, symptoms, flow), basal body temperature as measured by a thermometer, and ovulation and progesterone test results via apps installed on their iPhone. Additionally, participants were provided with an Apple Watch and a wrist-worn hardware prototype wrist-worn sleep band to collect physiological sensor data. Both menstrual cycle information and physiological sensor data stored on the participants' iPhone prior to enrolling in the study (up to 18 months) was also collected. This study aimed to collect data from females aged 14 and older who are currently menstruating with irregular and regular menstrual cycles.

02

Conditions studied

  • Menstruation

Keywords

  • menstruation
  • ovulation
  • menstrual cycle
03

In context

Lead sponsor

Apple Inc. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Contract research organization

Eligibility criteria

  • At least 14 years of age (19 for residents of Alabama and Nebraska and 21 for residents of Mississippi)
  • Can communicate in written and spoken English
  • Own functioning iPhone iOS 14 or later, with access to reliable data plan and Wifi
  • Access to reliable Wifi in the bedroom
  • Willingness to participate in remote visits and follow study procedures for the duration of the study, including use of Apple Watch and a wrist-work hardware prototype
  • Able to read and understand the written consent form
  • Reside in the US for the duration of the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
698 participants (actual)
Patient registry
No

Groups and cohorts

  • Menstrual patterns

    Regular menstrual cycles and irregular menstrual cycles; irregular menstrual cycles are defined as having variation in menstrual cycles of greater than 2 days and less than 2 months

06

What researchers measure

Primary outcomes

  1. Retrospective ovulation day estimate

    Retrospective ovulation day estimation (algorithm uses multiple measurements including menstrual flow, urine ovulation prediction testing, basal body temperature, overnight aggregated wrist temperature)

    Time frame: 12 months

07

Study locations

1 site
  • Exponent
    Phoenix, Arizona 85027, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in May 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
May 10, 2023
StartActual
Jun 9, 2021
Primary completionActual
May 23, 2022
CompletionActual
May 23, 2022
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05852951
Lead sponsor
Apple Inc.
Collaborators
Exponent
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Jun 9, 2021
Primary completion
May 23, 2022
Completion
May 23, 2022
Last update
May 10, 2023

Study contacts

Bo Qing, PhD
principal investigator · Exponent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion